Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Psoriatic 1

Interventions

pembrolizumab 118 Carboplatin 101 Paclitaxel 62 Cisplatin 56 Gemcitabine 55 Pemetrexed 52 Bevacizumab 49 Docetaxel 44 Fluorouracil 39 Oxaliplatin 37 Dexamethasone 34 130-nm albumin-bound paclitaxel 33 atezolizumab 32 Leucovorin 32 Cetuximab 31 durvalumab 26 Nivolumab 25 Capecitabine 25 Rituximab 24 Prednisone 24 Fulvestrant 23 Cyclophosphamide 23 Lenalidomide 22 enzalutamide 21 venetoclax 20 Irinotecan 19 Letrozole 18 pomalidomide 16 apalutamide 16 daratumumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × risankizumab × 30 days × Clear all

NCT06641089 2026-05-18

IZAR-2

MoonLake Immunotherapeutics AG

Phase 3 Recruiting

Arthritis, Psoriatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡